Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03354039
Other study ID # TAMDMD
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 12, 2018
Est. completion date October 18, 2022

Study information

Verified date December 2022
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomised, double blind, placebo controlled, 48-week clinical trial with a core population (group A) of 79 ambulant 6.5 to 12 years old Duchenne's muscular dystrophy (DMD) patients that are under stable standard treatment of care with glucocorticoids. Furthermore, the investigators plan to include 6-20 non-ambulant patients who do not receive glucocorticoids (as parallel group B), 10 to 16 years old, to obtain efficacy and safety data in a broader DMD population. All patients will receive 20 mg of tamoxifen (TAM) or placebo once daily during 48 weeks. An open label extension (OLE) trial for participants of the TAMDMD main study will be performed. All TAMDMD patients on TAM or placebo are offered to enter this OLE.


Description:

This is a 48-week multicentre, parallel, randomised, double-blind, placebo controlled phase 3 safety and efficacy trial. There are two treatment arms: Tamoxifen (verum) and placebo (control), with treatment allocation of 1:1. The investigators plan to screen at least 79 and to enroll at least 71 ambulant DMD patients aged between 6.5 and 12 years (group A) and 6 - 20 non-ambulant DMD patients aged between 10 and 16 years (group B). In order to reach statistical power, 60 ambulant patients (group A) need to complete the trial. Treatment with 20 mg Tamoxifen once daily will be given for the total trial duration of 48 weeks. Only patients with glucocorticoids (standard treatment of care) will be included in group A (ambulant patients) and only non-glucocorticoid users in group B. At baseline as well as at the end of the study clinical, laboratory, and MRI measurements will be performed. These include the Motor Function Measure (MFM) scale, timed function tests, the 6 minute walking distance, quantitative muscle testing (QMT) and quantitative thigh muscle MRI, questionnaires. A physical examination, an ECG, vital signs as well as safety laboratory blood analyses will be performed at every visit. Furthermore, an x-ray of the hand and a dual energy x-ray absorptiometry (DEXA)-scan will be performed at baseline and at the end of the study. An open label extension (OLE) trial for participants of the TAMDMD main study will be performed. All TAMDMD patients on TAM or placebo are offered to enter this OLE. All OLE patients will receive 20 mg of TAM daily during 48 weeks. The same study specific assessments as in the double-blind randomized phase will be performed during the OLE phase


Recruitment information / eligibility

Status Completed
Enrollment 93
Est. completion date October 18, 2022
Est. primary completion date July 25, 2022
Accepts healthy volunteers No
Gender Male
Age group 78 Months to 16 Years
Eligibility Inclusion Criteria: Group A (ambulant patients) - Documented diagnosis of DMD by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e. absent or <5% of normal) on Western blot or immunostaining - Stable treatment with glucocorticoids >6 months (no significant change in dosage (>0.2mg/kg)) at screening; dosing adaptations according to weight change are allowed - Male gender - 6.5 to 12 years of age at time of screening - weight >20kg - ambulant patients - able to walk at least 350 meters in 6 minute walking distance test without assistance at screening - MFM D1 subdomain of the MFM scale >40% at screening - Ability to provide informed consent and to comply with study requirements - Patients harbouring a nonsense mutation treatable with the approved drug ataluren should be under stable ataluren treatment for at least 3 months or in case of nontolerance being off ataluren treatment for at least 3 months before screening Group B (non-ambulant patients) - Documented diagnosis of DMD by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e. absent or <5% of normal) on Western blot or immunostaining - Not using glucocorticoids for >6 months - Male gender - Non-ambulant patients (walking distance less than 10 meters) - 10 to 16 years of age at time of screening - Ability to provide informed consent and to comply with study requirements Open label extension - Recent participation and completion of TAMDMD study Exclusion Criteria: - Known individual hypersensitivity or allergy to tamoxifen or other ingredients/excipients of IMP - Female gender - Use of tamoxifen or testosterone within the last 3 months - Known or suspected malignancy - Other chronic disease or clinically relevant limitation of renal, liver or heart function - Known or suspected non-compliance - Any injury which may impact functional testing, e.g. upper or lower limb fracture - Planned or expected spinal fusion surgery during the study period (as judged by the Investigator; i.e. due to rapid progressing scoliosis), previous spinal fusion surgery is allowed if it took place more than 6 months prior to screening. - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders of the participant/parents (as judged by the investigator) - Concomitant participation in any other interventional trial (and up to 3 months prior to screening) - Use of CYP2D6 inhibitors or of CYP3A4 inducers (apart from glucocorticoids), platelet aggregation inhibitors and coumarin-type anti-coagulants - Use of drugs metabolized by CYP2C9, such as phenprocoumon, phenytoin, warfarin, celecoxib, fluvastatin, ginko biloba, St. John's wort and sulfamethoxazol - Galactosemia (lack of galactose-1-phosphat-uridylyltransferase or UDP-galactose-4-epimerase or galactokinase; Fanconi-Bickel-syndrome); congenital lack of lactase; glucose-galactose malabsorption - Presence of one or more of the following eye disorders: cataract, retinopathia, optic neuropathy, alteration of the cornea - Presence of one or more of the following laboratory abnormalities: anaemia, thrombocytopenia, leukopenia, neutropenia or agranulocytosis Group A: - Glucocorticoid naïve patients - Start of glucocorticoid treatment or change in dosage <6 month prior to screening (dosing adaptations according to weight change are allowed) Group B: - Glucocorticoid treated patients or patients that stopped glucocorticoid treatment <6 month prior to screening - Assisted ventilation of any kind necessary

Study Design


Intervention

Drug:
Tamoxifen
DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
Matching placebo
Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.

Locations

Country Name City State
France Hôpitaux Raymond Poincaré Garches
France Hôpital de Hautepierre Strasbourg
Germany DRK Klinik Berlin Westend Berlin
Germany Universitätsklinikum Essen Essen
Netherlands Radboud umc Nijmegen
Spain Hospital Sant Joan de Déu. UB Esplugues de Llobregat Barcelona
Spain Hospital Universitario Virgen del Rocío Sevilla
Switzerland University Children's Hospital Basel Basel
United Kingdom Royal Hospital for Children Glasgow
United Kingdom The Leeds Teaching Hospitals NHS Trust Leeds
United Kingdom Alder Hey Children's Hospital Liverpool

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Countries where clinical trial is conducted

France,  Germany,  Netherlands,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Patient reported outcome measured by PARS III questionnaire Personal Adjustment and Role Skills Scale (PARS-III) from baseline to week 48 under TAM treatment under TAM treatment compared to placebo. Baseline to week 48
Primary Reduction of disease progression To test if tamoxifen treatment, compared to placebo, reduces the progression of the disease in 6.5-12 years old ambulant DMD patients (Group A) by at least 50% (using the MFM D1 subscore as primary clinical endpoint). Baseline to week 48
Secondary Muscle function measured by D2 MFM subscore D2 MFM subscore from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
Secondary Muscle function measured by D3 MFM subscore D3 MFM subscore from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
Secondary Muscle function measured by North Star Ambulatory Assessment North Star Ambulatory Assessment from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
Secondary Muscle function measured by proximal upper limb function Proximal upper limb function from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
Secondary Muscle function measured by 6 minute walking distance in meter 6 minute walking distance in meter from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
Secondary Muscle function measured by 10 meter walking time in seconds 10 meter walking time in seconds from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
Secondary Muscle function measured by time to rise from lying on the floor / supine up in seconds time to rise from lying on the floor / supine up in seconds from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
Secondary Muscle force measured by quantitative muscle testing (using Myogrip) Quantitative muscle testing (using Myogrip) from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
Secondary Muscle Degeneration measured by MRI Quantitative muscle MRI including muscle fat fraction (MFF) and T2 times of thigh muscles visualised by MRI from baseline to week 48 under TAM treatment compared to placebo. Baseline to week 48
See also
  Status Clinical Trial Phase
Completed NCT05575648 - Dual Task in Duchenne Muscular Dystrophy N/A
Terminated NCT03907072 - Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy Phase 2/Phase 3
Not yet recruiting NCT06450639 - An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy Phase 2
Completed NCT04335942 - Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor N/A
Active, not recruiting NCT04906460 - Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) Phase 1/Phase 2
Active, not recruiting NCT02500381 - Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) Phase 3
Enrolling by invitation NCT05967351 - A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study Phase 3
Recruiting NCT03067831 - Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy Phase 1/Phase 2
Recruiting NCT01834040 - Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy Phase 1/Phase 2
Completed NCT02246478 - A Study of TAS-205 for Duchenne Muscular Dystrophy Phase 1
Active, not recruiting NCT01772043 - Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping N/A
Terminated NCT01168908 - Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Phase 2
Completed NCT00758225 - Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension) Phase 2
Completed NCT03680365 - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Recruiting NCT03513367 - The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
Recruiting NCT05712447 - Duchenne Muscular Dystrophy Video Assessment Registry
Recruiting NCT01484678 - Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Completed NCT03319030 - Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
Terminated NCT01753804 - A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy. N/A
Completed NCT02530905 - Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients Phase 1